Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816500 | 0.85 | MAPK14 (0.67) | KMT2AMAPK14NPC1 | |
| SCHEMBL4820863 | 0.82 | MAPK14 (0.74) | KMT2AMAPK14NPC1RAB9AKCNK3 | |
| SCHEMBL5380271 | 0.81 | MAPK14 (0.64) | MAPK14NPC1RAB9AHPGDKDM4E | |
| SCHEMBL4818830 | 0.80 | MAPK14 (0.72) | KMT2AMAPK14KCNK3KCNK9 | |
| SCHEMBL4812867 | 0.79 | MAPK14 (0.71) | KMT2AMAPK14 | |
| SCHEMBL5665519 | 0.79 | MAPK14 (0.64) | KMT2AMAPK14NPC1RAB9AHPGD | |
| SCHEMBL4812425 | 0.78 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL5376345 | 0.78 | MAPK14 (0.65) | KMT2AMAPK14NPC1RAB9AHPGD | |
| SCHEMBL5371754 | 0.78 | MAPK14 (0.68) | KMT2AMAPK14 | |
| SCHEMBL5381526 | 0.78 | MAPK14 (0.68) | KMT2AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142476-A1 | Biphenyl-Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-06-21 | — | — | US | claimed |
| US-7183297-B2 | Biphenyl-derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-27 | — | — | US | claimed |
| US-20070142476-A1 | Biphenyl-Derivatives as p38 Kinase Inhibitors | GLAXO GROUP LIMITED | 2007-06-21 | — | — | US | disclosed |
| US-7183297-B2 | Biphenyl-derivatives as p38-kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-20040249161-A1 | For therapy of rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome | GLAXO GROUP LIMITED (GB) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142476-A1 | Biphenyl-Derivatives as p38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPK3 | KMT2A 3319/4885MAPK14 15/4885NPC1 1221/4885 |
| US-20040249161-A1 | For therapy of rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome | MAPK1, HSF1, TLR1 | KMT2A 4215/4885MAPK14 58/4885NPC1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.